FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma By Ogkologos - November 6, 2025 165 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DREAMM-7 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Retifanlimab Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over Standard Therapy in Patients with HR-positive, HER2-positive MBC FDA Grants Traditional Approval to Pirtobrutinib for Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma MOST POPULAR FDA Grants Accelerated Approval to Encorafenib with Cetuximab and mFOLFOX6 for... January 24, 2025 Common anti-inflammatory drug could boost cancer immunotherapy May 26, 2021 Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated... June 11, 2025 How People With Cancer Can Benefit From Online Therapy October 22, 2020 Load more HOT NEWS Nivolumab vs Sorafenib in First-Line Treatment of Advanced Hepatocellular Carcinoma Foodie Fridays: Farmer’s Market Finds Lazertinib Demonstrates Significant Efficacy Improvement Compared with Gefitinib in the First-Line... FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο
